U.S., Jan. 29 -- ClinicalTrials.gov registry received information related to the study (NCT06796361) titled 'Role of the Serotonin 2A Receptor in Psilocybin-induced Altered States of Consciousness' on Jan. 13.
Brief Summary: Psilocybin (active compound of "magic mushrooms") is a prototypical psychedelic substance that acts via agonism on serotonin (5-HT) 2A receptors. Psilocybin is rapidly metabolized into its active metabolite psilocin. Psilocybin is currently under investigation as potential treatment for various neuropsychiatric disorders. Psilocybin is also widely used for recreational purposes and as research tool in neuroscience. Besides its current clinical development, a clear characterization of the dose-response relationship of p...